Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a single arm window of opportunity trial conducted in patients with early stage
triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase
(PARP) inhibitor will increase expression of programmed cell death-1 with ligand (PD-L1) in
triple negative breast tumors.